201
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Clinical characteristics of resistant hypertension evaluated by ambulatory blood pressure monitoring

, , , , , & show all
Pages 454-458 | Received 22 May 2013, Accepted 12 Aug 2013, Published online: 28 Oct 2013

References

  • Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52
  • Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:3–107
  • Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305–15
  • Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med 2009;169:874–80
  • Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87
  • National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London: Royal College of Physicians (UK); 2011 Aug. Available from: http://www.nice.org/uk/guidance/CG127/Guidance [last accessed 3 Jan 2013]
  • Ohta Y, Matsumura K, Tsuchihashi T, et al. Improvement of blood pressure control in a hypertension clinic in Japan: a 15-year follow-up study. Clin Exp Hypertens 2009;31:553–39
  • Tanaka T, Okamura T, Yamagata Z, et al. Awareness and treatment of hypertension and hypercholesterolemia in Japanese workers: the High-risk and Population Strategy for Occupational Health Promotion (HIPOP-OHP) study. Hypertens Res 2007;30:921–8
  • Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403--19
  • Moser M, Setaro JF. Clinical practice: resistant or difficult-to-control hypertension. N Engl J Med 2006;355:385–92
  • Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011;57:1076–80
  • Oikawa T, Obara T, Ohkubo T, et al. Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements: the J-HOME study. J Hypertens 2006;24:1737–43
  • Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42
  • Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92
  • National Kidney Foundation. Executive summary of the kidney disease outcomes quality initiative. Am J Kidney Dis 2002;39:S17–31
  • JCS Joint Working Group. Guidelines for the clinical use of 24 hour ambulatory blood pressure monitoring (ABPM) (JCS 2010): digest version. Circ J 2012;76:508–19
  • Redon J, Campos C, Narciso ML, et al. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998;31:712–18
  • Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005;18:1422–8
  • Shafi S, Sarac E, Tran H. Ambulatory blood pressure monitoring in patients with chronic kidney disease and resistant hypertension. J Clin Hypertens 2012;14:611–17
  • de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57:898–902
  • Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008;168:2340–6
  • Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens 2008;10:239–44
  • Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271–7
  • Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int 2006;69:967–73
  • Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002;4:393–404
  • Saelen MG, Prøsch LK, Gudmundsdottir H, et al. Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate-to-severe reductions in renal function. Blood Press 2005;14:170–6
  • Khawaja Z, Wilcox CS. Role of the kidneys in resistant hypertension. Int J Hypertens 2011;2011:143471 . Available from: http://dx.doi.org/10.4061/2011/143471 [last accessed 4 Dec 2012]
  • Matsumura K, Fujii K, Oniki H, et al. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006;19:13–18

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.